Quarterly report · Q2
4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥443.9bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥228.6bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥403.3bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥206.0bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.8bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥56.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥25.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥66.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥36.6bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥54.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥25.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥27.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥27.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥1.75T | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.66T | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥487.4bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.26T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.17T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.26T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥187.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥212.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥53.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥60.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥36.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥30.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥37.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥67.27 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥36.99 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥53.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.75 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥67.24 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥36.97 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥53.35 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.74 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.1% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.6% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥119m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥265.7bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥57.6bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥94.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥443.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥76.6bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥275m |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥74.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥235.4bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥93.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥403.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥70.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 690
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -140000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -122000000 | JPY |
| Proceeds from sales of shares of subsidiaries and affiliates inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sales of shares of subsidiaries and affiliates inv cf IFRS | CurrentYTDDuration | 2921000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -31613000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -36105000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1YTDDuration | 670000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1YTDDuration | -670000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -614000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -646000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1YTDDuration | － | JPY |
| Redemption of bonds fin cf IFRS | CurrentYTDDuration | -10000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -3734000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -3713000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -14420000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -2000000 | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -5580000000 | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | － | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -13593000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -15630000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -37942000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -29992000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 16508000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 12510000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | 7298000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -8000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 187322000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 212550000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 187313000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 235405000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 93805000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 73980000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 403191000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 124000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 403316000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 52905000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 8147000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 9102000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 70154000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | 275000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration | 70429000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -4446000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -5060000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReportableSegmentsMember | -9506000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReconcilingItemsMember | -11000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration | -9518000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |